Small-molecule inhibitors of BACE1 as Alzheimer disease treatment

Busscher, Stefan (2021) Small-molecule inhibitors of BACE1 as Alzheimer disease treatment. Bachelor's Thesis, Biology.

Preview	Text Premaster Thesis BMS Stefan Busscher.pdf Download (601kB) | Preview
	Text toestemming.pdf Restricted to Registered users only Download (162kB)

Abstract

Alzheimer disease (AD) is the most common aging-related neurodegenerative disease worldwide that gets worse over time. Characteristic for AD are the extracellular senile plaques and intracellular neurofibrillary tangles that consist of aggregated hyperphosphorylated tau proteins that can be found in the brains and damage the brain. These plaques mostly consist of Amyloid-, which is produced by the cleavage of the amyloid precursor protein by an enzyme called -site amyloid precursor protein cleaving enzyme 1, or BACE1. Since BACE1 is thought to play a crucial role in AD pathogenesis, BACE1 inhibitors are studied as a potential treatment against this disease. The small-molecule inhibitors LY2811376 and Verubecestat have been studied in animal models and in clinical trials. These research findings are discussed in this report. Up until now, no BACE1 inhibitors have improved cognition in AD patients or improved AD pathology. Because of this, future research should not only focus on the amyloid cascade hypothesis and BACE1 inhibitors, but also other types of treatments such as monoclonal antibodies that target amyloid- or hyperphosphorylated tau.

Item Type:	Thesis (Bachelor's Thesis)
Supervisor name:	Eisel, U.L.M. and Schmidt, M.
Degree programme:	Biology
Thesis type:	Bachelor's Thesis
Language:	English
Date Deposited:	25 Mar 2021 15:02
Last Modified:	25 Mar 2021 15:02
URI:	https://fse.studenttheses.ub.rug.nl/id/eprint/24123

Actions (login required)

View Item